This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
L-proline amide hydrolase (EC 3.5.1.101, S-stereoselective piperazine-2-tert-butylcarboxamide hydrolase, LaaA, L-amino acid amidase) is an enzyme with systematic name (S)-piperidine-2-carboxamide amidohydrolase. It catalyses several related hydrolysis reactions. For example, prolinamide is converted to proline:
== External links == International Rett Syndrome Foundation Rett UK Support and Research Charity Reverse Rett UK Rett Registry UK Rett Syndrome Research Trust Ensembl Gene ref Protein ref GeneCard RettBASE: IRSA MECP2 Variation Database Archived 2005-12-17 at the Wayback Machine GeneReview/NIH/UW entry on MECP2-Related Disorders GeneReviews/NCBI/NIH/UW entry on MECP2 Duplication Syndrome UK Site for Families Affected by MECP2. Site for Families Affected by MECP2. Site officiel français sur la duplication MeCP2
However, a sufficiently chemically skilled malicious actor could extract a volatile species from inert material and/or achieve a similar effect of dispersion by physically grinding the inert matrix into a fine dust.
Similarly, in mice, a postprandial increase in hepatic leptin expression has also been reported. However, in grass carp, intraperitoneal injection of recombinant leptin only alters the appetite on the first day, and does not influence food intake during the ensuing 12 days. At present, the data for Atlantic salmon are therefore quite different and suggest that leptin expression in this species may have a complex lipostatic function.
Sources: en.wikipedia.org
Winemakers can track the progression of malolactic fermentation by paper chromatography or with a spectrophotometer. The paper chromatography method involves using capillary tubes to add small samples of the wine to chromatograph paper. The paper is then rolled and placed in a jar filled with a butanol solution containing bromocresol green indicator dye for several hours. After the paper is pulled out and dried, the distance of yellow-colored "splotches" from the base line denotes the presence of various acids, with tartaric being closest to the baseline followed by citric, malic, and finally lactic acids near the top of the paper. A significant limitation to paper chromatography is that it will not show exactly how much malic is still remaining in the wine, with the size of the "splotch" on the paper having no correlation to a quantitative figure. The sensitivity of the paper is also limited to a detection threshold of 100–200 mg/L while most measurements of "MLF stability" target a malic level of less than 0.03 g/L (30 mg/L). The enzymatic method allows for a quantitative measurement of both malic and lactic acids, but requires the expense of reagent kits and a spectrophotometer that can measure absorbance values at 334, 340, or 365 nm.
The substrates of this enzyme are mevalonic acid, coenzyme A, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), reduced NADH, and two protons. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (R)-mevalonate:NAD+ oxidoreductase (CoA-acylating). Other names in common use include beta-hydroxy-beta-methylglutaryl coenzyme A reductase, beta-hydroxy-beta-methylglutaryl CoA-reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and hydroxymethylglutaryl coenzyme A reductase.
Both 123I and 125I emit copious low energy Auger electrons after their decay, but these do not cause serious damage (double-stranded DNA breaks) in cells, unless the nuclide is incorporated into a medication that accumulates in the nucleus, or into DNA (this is never the case is clinical medicine, but it has been seen in experimental animal models). Iodine-125 is also commonly used by radiation oncologists in low dose rate brachytherapy in the treatment of cancer at sites other than the thyroid, especially in prostate cancer. When 125I is used therapeutically, it is encapsulated in titanium seeds and implanted in the area of the tumor, where it remains. The low energy of the gamma spectrum in this case limits radiation damage to tissues far from the implanted capsule. Iodine-125, due to its suitable longer half-life and less penetrating gamma spectrum, is also often preferred for laboratory tests that rely on iodine as a tracer that is counted by a gamma counter, such as in radioimmunoassaying. 125I is used as the radiolabel in investigating which ligands go to which plant pattern recognition receptors (PRRs).
Sources: en.wikipedia.org
=== Skeletal muscle === In 1998, skeletal muscle was identified as an endocrine organ due to its now well-established role in the secretion of myokines. The use of the term myokine to describe cytokines and other peptides produced by muscle as signalling molecules was proposed in 2003.
While giving evidence under oath, former Post Office chairman Henry Staunton tells a parliamentary hearing on the Horizon IT scandal that current Post Office chair Nick Read is under internal investigation. 28 February The Duke of Sussex loses a High Court challenge against the UK government's decision to downgrade his security status when he stopped being a working royal. A study in the British Medical Journal links ultra-processed foods to 32 negative health impacts, including a higher risk of heart disease, cancer, type 2 diabetes, adverse mental health and early death. Following a trial at the High Court in Glasgow, Iain Packer is found guilty of the April 2005 murder of Emma Caldwell, a sex worker whose body was found in woods five weeks after she disappeared from Glasgow. Packer, who is also convicted of 32 other offences against women, including rapes and sexual assaults, is sentenced to at least 36 years in prison, the second longest prison sentence to be handed out by a Scottish court. 29 February 2024 Rochdale by-election: In an unusually chaotic by-election, former MP George Galloway resoundingly wins for the Workers Party of Britain, marking his return to parliament. Independent candidate David Tully comes second, with the Conservative candidate Paul Ellison coming third. Both the Labour and Green Party candidates were disowned by their respective parties. Angiolini Inquiry: The public inquiry into the murder of Sarah Everard finds that her killer Wayne Couzens should never have been a police officer, and that opportunities to detect his offending were missed.
Each parent with the condition poses a 50% risk of passing the genetic defect on to any child due to its autosomal dominant nature. Most individuals with MFS have another affected family member. About 75% of cases are inherited. On the other hand, about 15–30% of all cases are due to de novo genetic mutations; such spontaneous mutations occur in about one in 20,000 births. Marfan syndrome is also an example of dominant negative mutation and haploinsufficiency. It is associated with variable expressivity; complete penetrance has been definitively documented.
== Adverse effects == Various adverse effects may occur according to the pre-workout product and dose of supplement consumed. Some potential side effects of taking pre-workout could include nausea and skin irritation. One ingredient that causes this to happen is beta-alanine. Beta-alanine is commonly included in pre-workouts. It is known to temporarily create an itching sensation on skin. This sensation is harmless. It typically occurs shortly after consumption and is dose dependent. Other adverse effects have been shown to arise when the product contains ingredients such as synephrine and caffeine. Synephrine is often used as a weight loss supplement and commonly found in pre-workout. Synephrine has been found to cause heart problems and other cardiovascular issues. Caffeine is also a common ingredient found in pre-workout which may cause an increase in blood pressure. Another issue that may arise is a higher risk in cardiac and liver related diseases due to the high concentration of caffeine in these types of products.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.